Response to Comments: MolDX: Blood Product Molecular Antigen Typing

This document is a Response to Comments for MolDX LCD L38249 and records that the LCD title was changed to 'MolDX: Blood Product Molecular Antigen Typing' and provides the comment (2019-10-30 to 2019-12-04), notice (begin 2020-09-17), and effective (2020-11-01) dates. It does not contain specific coverage indications, limitations, frequency limits, or claim documentation requirements — refer to the full MolDX LCD L38249 for substantive coverage criteria and requirements.

"This Response to Comments document does not provide coverage indications; refer to MolDX LCD L38249 (Erythrocyte/Blood Product Molecular Antigen Typing) for specific coverage criteria."

Sign up to see full coverage criteria, indications, and limitations.